HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Methylnaltrexone Bromide

HCID 5361917
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
73232-52-7
Standard SMILES
C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.[Br-]
InChIKey
IFGIYSGOEZJNBE-KNLJMPJLSA-N
Molecular formula
C21H26BrNO4
Average molar mass
436.3 g/mol
Monoisotopic mass
435.10452041

Overview

Methylnaltrexone Bromide is the bromide salt form of methylnaltrexone, a methyl derivative of noroxymorphone with selective, peripherally-acting mu-opioid receptor antagonistic activity. Methylnaltrexone displaces opioids from peripheral opioid receptors in the gastrointestinal tract, the bladder, and the skin, thereby reversing the opioid-related peripheral side-effects, such as constipation, urinary retention, and pruritis, respectively. Unlike naltrexone and due to the presence of a positively charged nitrogen atom in methylnaltrexone, this agent does not cross the blood-brain barrier and does not affect the centrally-mediated analgesic effect of opioids.

Names & identifiers

Preferred name
Methylnaltrexone Bromide
IUPAC
(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-one bromide
English name
Naltrexone methylbromide
Molecular formula
C21H26BrNO4
Molecular weight
436.35

Names & synonyms

Methylnaltrexone bromideRelistorN-Methylnaltrexone BromideNaltrexone methobromideMRZ-2663BRMOA-728bromuro de metilnaltrexonabromure de methylnaltrexoneMRZ2663BRMOA728DTXSID30868236NALTREXONE METHYLBROMIDE
Show more names
MNTXUnii-rfo6il3D3mAdamantane Impurity 52Methylnatrexone bromideMethyhaaltrexone broMide
methylnaltrexoni bromidumRefChem:56830A06AH01DTXCID40820845morphinan-17-ium-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-, bromide, (5alpha,17R)-916055-92-0RFO6IL3D3M73232-52-7

Database identifiers

CAS
73232-52-7
PubChem CID
5361917
DTXSID
DTXSID30868236
ChEMBL
CHEMBL1201770
EC Number
615-932-9

Properties

Computed structural properties

Topological polar surface area
66.8 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
5
Rotatable bonds
2
Heavy atoms
27
Formal charge
0
Complexity
664

Experimental & physicochemical properties

Human Drugs · 4 items

Breast Feeding; Lactation; Milk, Human; Narcotic Antagonists

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Physicochemical properties

Melting point
237 · 237-239°C
storage temp.
-20 °C · -20°C
solubility
2 O: · H2O: ≥5mg/mL
form
powder
color
white to beige
Water Solubility
2 O: · H2O: ≥5mg/mL
Stability
Hygroscopic
InChIKey
IFGIYSGOEZJNBE-NIWJRJBUNA-N
SMILES
O[C@]12CCC(=O)[C@]3([H])OC4=C(C=CC5C[C@@]1([H])[N+](C)(CC1CC1)CC[C@@]23C4=5)O.[Br-] |&1:1,6,15,25,r|
NCI Dictionary of Cancer Terms
methylnaltrexone bromide; Relistor
FDA UNII
6 IL3D3M · RFO6IL3D3M

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H301 (66.7%): Toxic if swallowed [Danger Acute toxicity, oral]

P233, P260, P261, P264, P270, P271, P272, P273, P280, P284, P301+P316, P301+P317, P302+P352, P304+P340, P317, P321, P330, P333+P317, P342+P316, P362+P364, P391, P403, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 57 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazard Classes and CategoriesAcute Tox. 3 (66.7%)

Toxicology

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Methylnaltrexone bromide

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

wgk
3
rtecs
QD0188550
ridadr
UN 2811 6.1 / PGIII
hs_code
2934990002
risk_code
25-50
Signal word
Danger
Symbol(GHS)
GHS06,GHS09

Chemistry & industry

Pharmacology

ATC Code · 3 items

A06AH01

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

FDA Pharmacological Classification · 2 items

METHYLNALTREXONE BROMIDE

Opioid Antagonists [MoA]; Quaternary Ammonium Compounds [CS]; Opioid Antagonist [EPC]

MeSH Pharmacological ClassificationAgents inhibiting the effect of narcotics on the central nervous system.
Applications · 4 items

DescriptionThe widespread efficacy of opioids in treating patients with moderate to severe acute and chronic pain is often accompanied by untoward side effects. In particular, opioid-induced bowel dysfunction is one of the more common and debilitating consequences afflicting up to 50% of patients. To counteract the peripherally-mediated adverse effects, opioid antagonists such as naloxone, naltrexone, and nalmephene are sometimes prescribed. The latest market entry exploits a strategic modification of naltrexone to lower its lipid solubility and increase its polarity: quaternization of the amine of naltrexone by methylation (methyl bromide) prevents crossing of the blood–brain barrier thereby creating an effective peripheral antagonist. Despite a loss of potency upon methylation, methylnaltrexone antagonizes opioid binding at m-opioid receptors with an IC50 of 70 nM. Its affinity for k-opioid receptors is approximately eightfold less (IC50= 575 nM) with no significant binding to d-opioid, orphanin, or non-opioid receptors. Methylnaltrexone bromide has been approved for the treatment of opioid-induced constipation in patients with advanced illness receiving palliative care.Regarding metabolism, methylnaltrexone bromide is eliminated primarily as intact drug (85% based on administered radioactivity) by slightly more renal than hepatic clearance.The most common adverse events were abdominal pain and flatulence followed by nausea, dizziness, and diarrhea.

UsesMethylnaltrexone bromide has been used as a drug to measure plasma protein binding (PPB), permeability (Pm) and the membrane coefficient (KIAM) for the prediction of blood brain barrier (BBB) penetration. It is also used as a mu-opioid receptor (MOR) antagonist to abrogate morphine tolerance and opioid-induced hyperalgesia (OIH).

Related reactions

5 records
New reaction record
HRID 47066 reaction equation
HRID 47066As product
HRID 533704 reaction equation
HRID 533704As product
HRID 1482461 reaction equation
HRID 1482461As reactant
HRID 1798791 reaction equation
HRID 1798791As product
HRID 2243414 reaction equation
HRID 2243414As product

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
NCI Drug Dictionary
methylnaltrexone bromide
ATC code
6 AH01 · A06AH01
UNSPSC Code
41116107 · 41116107
NACRES
77 · NA.77
Symbol(GHS)
6 · GHS06,GHS09
Signal word
Danger
Hazard statements
301 · H301-H400
Precautionary statements
273 · P273-P301+P310
target organs
Gastrointestinal tract
Hazard Codes
T,N
Risk Statements
25 · 25-50
Safety Statements
45 · 45-61
RIDADR
2811 · UN 2811 6.1 / PGIII
WGK Germany
3 · 3
RTECS
188550 · QD0188550
HS Code
2934990002 · 2934990002
Storage Class
11 · 11 - Combustible Solids
Hazard Classifications
2 Oral · STOT SE 2 Oral
hazard_code
T,N
safety_code
45-61
Storage Class
11 - Combustible Solids
target organs
Gastrointestinal tract
Hazard statements
H301-H400
Hazard Classifications
STOT SE 2 Oral
Precautionary statements
P273-P301+P310

UsesA metabolite of Naltrexone (N285750). Methylnaltrexone (MNTX), a selective μ-opioid receptor antagonist, functions as a peripherally acting receptor antagonist in tissues of the gastrointestinal tract.

General DescriptionMethylnaltrexone does not cross blood brain barrier and does not affect the opioid effects in the brain, such as analgesia. It is used to treat opioid-induced constipation (OIC).